AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18208877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg PO
Number of subjects: 313
Study 18208877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 18208877 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (IVMP) 1,000 mg/day for three days every other month
Number of subjects: 313
Study 18208877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNbeta-1a) 30 mcg IM weekly
Number of subjects: 313
Study 16436547 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (maximum dose 1.8 mg/kg/day; n = 102)
Number of subjects: 153
Study 16436547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 153
Study 16436547 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 153
Study 16436547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 12472392 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (CRT) followed by surgery
Number of subjects: 0
Study 12472392 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 12472392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic CR
Number of subjects: 0
Study 9429680 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured communication program (discussion with a nurse, informational pamphlet, daily telephone call)
Number of subjects: 30
Study 9429680 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured communication program
Number of subjects: 30
Study 9429680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured communication program)
Number of subjects: 30
Study 7813254 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 3:1 ratio
Number of subjects: 36
Study 7813254 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 1:3 ratio
Number of subjects: 36
Study 7813254 — intervention group
Group type: COMPARATOR
Intervention: Unoperated obese patients
Number of subjects: 36
Study 2757885 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled NAAGA (60 mg thrice daily for 1 week)
Number of subjects: 12
Study 2757885 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study 180199 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of adenine arabinoside/kg per day
Number of subjects: 42
Study 180199 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of adenine arabinoside/kg per day
Number of subjects: 42
Study 180199 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of adenine arabinoside/kg per day
Number of subjects: 42
Study 180199 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of adenine arabinoside/kg per day
Number of subjects: 42
Study 180199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7305144 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine electrocardiogram and serum creatine phosphokinase tests
Number of subjects: 176
Study 7305144 — intervention group
Group type: COMPARATOR
Intervention: No diagnostic tests withheld
Number of subjects: 176
Study 31697972 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K 62.5 mg
Number of subjects: 392
Study 31697972 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K 125 mg
Number of subjects: 392
Study 31697972 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K 250 mg
Number of subjects: 392
Study 31697972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 31697972 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K (all doses)
Number of subjects: 392
Study 31783602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU loading dose of cholecalciferol followed by 4000 IU daily for 16 weeks)
Number of subjects: 26
Study 31783602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 16 weeks)
Number of subjects: 26
Study 30286855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-therapy COMBO stent
Number of subjects: 3614
Study 26228576 — intervention group
Group type: EXPERIMENTAL
Intervention: New chewable benazepril hydrochloride tablet (0.5 mg/kg p.o.)
Number of subjects: 22
Study 26228576 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation (Fortekor®)
Number of subjects: 22
Study 24428236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention with a 45% reduction in unhealthy alcohol consumption
Number of subjects: 0
Study 24428236 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy alcohol consumption behaviors
Number of subjects: 0
Study 22065305 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of norgestomet implant for 9 days with 500 IU PMSG at implant removal
Number of subjects: 80
Study 22065305 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of norgestomet implant for 9 days without PMSG
Number of subjects: 80
Study 22065305 — intervention group
Group type: COMPARATOR
Intervention: Control group without hormonal treatment
Number of subjects: 80
Study 19713152 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-4658 (0.09 mg in 900 microL saline)
Number of subjects: 7
Study 19713152 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-4658 (0.9 mg in 900 microL saline)
Number of subjects: 7
Study 19713152 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 17767200 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% Dexamethasone sodium phosphate phonophoresis (PH)
Number of subjects: 50
Study 17767200 — intervention group
Group type: COMPARATOR
Intervention: 0.4% Dexamethasone sodium phosphate iontophoresis (ION)
Number of subjects: 50
Study 15231012 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day and 5 mg/day
Number of subjects: 1099
Study 15231012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study 15231012 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (combined 5 mg and 10 mg groups)
Number of subjects: 1099
Study 15231012 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of alendronate
Number of subjects: 1099
Study 12032117 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 21
Study 12032117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9836078 — intervention group
Group type: COMPARATOR
Intervention: Bone resorption in IBD patients
Number of subjects: 149
Study 9836078 — intervention group
Group type: COMPARATOR
Intervention: Bone formation in IBD patients
Number of subjects: 149
Study 9836078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of osteopenia and osteoporosis in IBD patients
Number of subjects: 149
Study 9836078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone metabolism imbalance in IBD patients
Number of subjects: 149
Study 7926142 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva P measurements
Number of subjects: 21
Study 7926142 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P measurements
Number of subjects: 21
Study 7926142 — intervention group
Group type: EXPERIMENTAL
Intervention: Single plasma P concentration (8:00 A.M.)
Number of subjects: 21
Study 7926142 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma pulse frequency, mean pulse interval, pulse width, pulse amplitude, and 24-hour mean P level
Number of subjects: 21
Study 7926142 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated saliva P samples
Number of subjects: 21
Study 2591258 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyI:C
Number of subjects: 90
Study 2591258 — intervention group
Group type: COMPARATOR
Intervention: Inosine
Number of subjects: 90
Study 2591258 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal followed by PolyI:C
Number of subjects: 90
Study 2591258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1098888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.3 mg for seven days)
Number of subjects: 30
Study 30085176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D < 20 ng/mL or 50 nmol/L) in PPCOS II
Number of subjects: 1254
Study 30085176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency in pregnant subjects from both studies
Number of subjects: 1254
Study 30085176 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D deficiency in AMIGOS
Number of subjects: 1254
Study 28040368 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based information and self-help program with therapist contact
Number of subjects: 62
Study 28040368 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 62
Study 25534913 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-β
Number of subjects: 0
Study 25534913 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 21950455 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation from a third party
Number of subjects: 2
Study 21950455 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization of the transgression
Number of subjects: 2
Study 21606192 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg for 6 months
Number of subjects: 10
Study 21606192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20050483 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading handover (written communication between nurses)
Number of subjects: 0
Study 20050483 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral handover
Number of subjects: 0
Study 16948972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice a day) and Vitamin E (400 IU per day)
Number of subjects: 40
Study 16948972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin therapy)
Number of subjects: 40
Study 15277403 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 20
Study 15277403 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 20
Study 15277403 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 20
Study 11783684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic fetal monitoring (EFM)
Number of subjects: 0
Study 11783684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent auscultation (IA)
Number of subjects: 0
Study 9435196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisofylline (LSF) at doses of 1, 2, or 3 mg/kg every 24 hr for 3 days by 10 min intravenous infusion
Number of subjects: 12
Study 8010459 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4 mg and indomethacin 50 mg (Group A)
Number of subjects: 80
Study 8010459 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine 0.4 mg (Group B)
Number of subjects: 80
Study 8010459 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg (Group C)
Number of subjects: 80
Study 8010459 — intervention group
Group type: COMPARATOR
Intervention: No drug (Group D)
Number of subjects: 80
Study 2776288 — intervention group
Group type: EXPERIMENTAL
Intervention: Menicon SF‐P rigid gas permeable (RGP) contact lenses
Number of subjects: 25
Study 2776288 — intervention group
Group type: EXPERIMENTAL
Intervention: Menicon EX rigid gas permeable (RGP) contact lenses
Number of subjects: 25
Study 799980 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine ('Numotac') 10 mg
Number of subjects: 39
Study 799980 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine ('Numotac') 20 mg
Number of subjects: 39
Study 799980 — intervention group
Group type: COMPARATOR
Intervention: Isoetharine ('Numotac')
Number of subjects: 39
Study 30730043 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational HIV/STI prevention intervention
Number of subjects: 108
Study 27789452 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling/SWI
Number of subjects: 92
Study 27789452 — intervention group
Group type: COMPARATOR
Intervention: Conventional MR imaging
Number of subjects: 92
Study 24444862 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training
Number of subjects: 86
Study 24444862 — intervention group
Group type: COMPARATOR
Intervention: Commercial computer games (Control)
Number of subjects: 86
Study 25632575 — intervention group
Group type: COMPARATOR
Intervention: Medication (Aspirin and Panax Notoginseng Saponins)
Number of subjects: 160
Study 25632575 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160
Study 25632575 — intervention group
Group type: COMPARATOR
Intervention: Tongxinluo
Number of subjects: 160
Study 25632575 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Tongxinluo
Number of subjects: 160
Study 21730216 — intervention group
Group type: COMPARATOR
Intervention: Soy protein intake (median of 30 g/d)
Number of subjects: 43
Study 19389902 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery for TTTS with cervical length >2.5 cm
Number of subjects: 99
Study 19389902 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery for TTTS with cervical length 2 to 2.5 cm
Number of subjects: 99
Study 19389902 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery for TTTS with cervical length 0.5 to 1.9 cm
Number of subjects: 99
Study 17341994 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg, titrated to 40 mg at week 4, remained at 40 mg at week 8 and 12
Number of subjects: 0
Study 17341994 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg, titrated to 50 mg twice daily at week 8
Number of subjects: 0
Study 17341994 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg, titrated to 320 mg at week 8
Number of subjects: 0
Study 17341994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15231078 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron administered once a week (60 mg as 300-mg ferrous sulfate tablets)
Number of subjects: 150
Study 15231078 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron administered twice a week (60 mg as 300-mg ferrous sulfate tablets)
Number of subjects: 150
Study 15231078 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron administered once a day (60 mg as 300-mg ferrous sulfate tablets)
Number of subjects: 150
Study 11727882 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 182
Study 11727882 — intervention group
Group type: COMPARATOR
Intervention: Adolescent group therapy (AGT)
Number of subjects: 182
Study 11727882 — intervention group
Group type: COMPARATOR
Intervention: Multifamily educational intervention (MEI)
Number of subjects: 182
Study 11727882 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFT
Number of subjects: 182
Study 9257209 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor plasma transfusion
Number of subjects: 16
Study 9257209 — intervention group
Group type: COMPARATOR
Intervention: Albumin 5% (Control)
Number of subjects: 16
Study 8506786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance newsletters
Number of subjects: 0
Study 8506786 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone hotline
Number of subjects: 0
Study 3326115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 10
Study 3326115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 10
Study 3326115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 2.5 mg
Number of subjects: 10
Study 3326115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (various doses)
Number of subjects: 10
Study 3326115 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo not specified)
Number of subjects: 10
Study 30414699 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval practice with sham tDCS
Number of subjects: 150
Study 30414699 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval practice with active anodal tDCS
Number of subjects: 150
Study 30414699 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval practice with active cathodal tDCS
Number of subjects: 150
Study 30414699 — intervention group
Group type: COMPARATOR
Intervention: Study practice with sham tDCS
Number of subjects: 150
Study 30414699 — intervention group
Group type: COMPARATOR
Intervention: Study practice with active anodal tDCS
Number of subjects: 150
Study 30414699 — intervention group
Group type: COMPARATOR
Intervention: Study practice with active cathodal tDCS
Number of subjects: 150
Study 26833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 25527295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost/timolol (bim/tim)
Number of subjects: 78
Study 25527295 — intervention group
Group type: COMPARATOR
Intervention: Fixed-combination dorzolamide/brimonidine/timolol (dorz/brim/tim)
Number of subjects: 78
Study 22308289 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF-mobilized peripheral blood mononuclear cells (G-PBMCs)
Number of subjects: 172
Study 22308289 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 172
Study 20376496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg before surgery and repeated after 12 hours
Number of subjects: 99
Study 20376496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 20376496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 99
Study 18693743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acai pulp
Number of subjects: 12
Study 18693743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acai juice
Number of subjects: 12
Study 18693743 — intervention group
Group type: EXPERIMENTAL
Intervention: Applesauce
Number of subjects: 12
Study 18693743 — intervention group
Group type: COMPARATOR
Intervention: Non-antioxidant beverage
Number of subjects: 12
Study 16154698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg buprenorphine i.v. and placebo pill s.l.
Number of subjects: 15
Study 16154698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine s.l. and saline 0.9% i.v.
Number of subjects: 15
Study 16154698 — intervention group
Group type: COMPARATOR
Intervention: saline 0.9% i.v. and placebo pill s.l.
Number of subjects: 15
Study 12810244 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 1% methyl nicotinate (MN)
Number of subjects: 20
Study 12810244 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis of 1% acetylcholine (ACh)
Number of subjects: 20
Study 12810244 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis of 1% sodium nitroprusside (SNP)
Number of subjects: 20
Study 10229309 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 100mg/day
Number of subjects: 259
Study 10229309 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 200mg/day
Number of subjects: 259
Study 10229309 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea alone
Number of subjects: 259
Study 10229309 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 259
Study 8628470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathologic examination of surgically removed pericystic samples
Number of subjects: 3
Study 8628470 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 3
Study 8628470 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 3
Study 8628470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical findings
Number of subjects: 3
Study 1333087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg b.d. or q.i.d.)
Number of subjects: 76
Study 1333087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (q.i.d.)
Number of subjects: 76
Study 1333087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 3913424 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (gastropulgit) - 2 bags
Number of subjects: 8
Study 3913424 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B (commercial product) - 2 bags
Number of subjects: 8
Study 3913424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30388596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (synthetic hormone analog of testosterone)
Number of subjects: 0
Study 30388596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30388596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 0
Study 29703749 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (MSCs)
Number of subjects: 162
Study 29703749 — intervention group
Group type: EXPERIMENTAL
Intervention: c-kit+ cardiac progenitor cells (CPCs)
Number of subjects: 162
Study 29703749 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MSCs and CPCs
Number of subjects: 162
Study 29703749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 27096210 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 33
Study 27096210 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary healing
Number of subjects: 33
Study 27096210 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 healthy volunteers)
Number of subjects: 33
Study 25567682 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AG)
Number of subjects: 0
Study 25567682 — intervention group
Group type: COMPARATOR
Intervention: Aerobic plus resistance training (RAG)
Number of subjects: 0
Study 25567682 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 24325903 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified miniscrew‐supported Herbst appliance (EG)
Number of subjects: 10
Study 24325903 — intervention group
Group type: COMPARATOR
Intervention: Conventional cast Herbst appliance (CG)
Number of subjects: 10
Study 20570237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intravitreal ranibizumab 0.5 mg and topically applied MMC (0.4 mg/mL for 2 min)
Number of subjects: 10
Study 20570237 — intervention group
Group type: COMPARATOR
Intervention: Topical MMC (0.4 mg/mL for 2 min) alone
Number of subjects: 10